ロード中...
Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
PURPOSE: We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC). PATIENTS AND METHODS: Patients with locally advanced HNC, including squamous and undiffer...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3018361/ https://ncbi.nlm.nih.gov/pubmed/21079141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.6423 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|